Competing interests
ONCOLOGY, CARD
L.V., O.I.I., S.B., M.C., N.A.M.B., E.C., H.G., K.S., C.E.L., I.K., I.A.M.M., M.d.M., J.J.L.v.G., J.B., M.G.J.v.D. and A.J. have no competing interests to declare. H.M.H. reports consultancy fees from Roche Diagnostics paid to the institute and is an advisor for SlideScore and Ellogon from Roche Diagnostics, outside the submitted work. M.d.B. received funding from Roche, AstraZeneca, Novartis, Pfizer, Eisai and Eli Lilly, outside the submitted work. R.S. reports non-financial support from Merck and Bristol Myers Squibb (BMS), research support from Merck, Puma Biotechnology and Roche and personal fees from Roche, BMS and Exact Sciences for advisory boards, all outside the scope of this paper. G.S.S. reports research funding to the institute from Merck, Agendia, AstraZeneca, Roche and Novartis and a consulting role for Novartis, Seattle Genetics and Biovica, outside the submitted work. K.E.d.V. reports research funding from Roche and is a consultant for Macomics, outside the scope of this work. T.N.S. is a consultant for Third Rock Ventures and is a stockholder and advisor in Allogene Therapeutics, Asher Bio, Celsius, Merus, Scenic Biotech and Neogene Therapeutics, outside this work. C.U.B. has received research grants from Novartis, BMS and NanoString, is a paid advisory board member for BMS, MSD, Roche, Novartis, GlaxoSmithKline, AstraZeneca, Pfizer, Lilly, GenMab and Pierre Fabre and holds ownership interest in Uniti Card, Neon Therapeutics and Forty Seven, all outside this submitted work. L.F.A.W. reports funding to the institute from Genmab BV. V.C.G.T.-H. reports research funding to the institute from Roche, Eisai, Pfizer, Novartis, Lilly, Daiichi Sankyo/AstraZeneca and Gilead Sciences, a consulting role from Pfizer, Lilly, Accord Healthcare and Novartis and honoraria from Novartis, Roche, Lilly and AstraZeneca, all outside this submitted work. C.P.S. has received research funding to the institute from Pfizer, Roche, Genentech, SNS Oncology, G1 Therapeutics, Abbvie, Synthon and CytoMx Therapeutics, outside this work. S.C.L. reports research funding to the institute from Roche/Genentech, AstraZeneca, BMS, Tesaro, Merck, Immunomedics, Eurocept Pharmaceuticals, Agendia and Novartis and a consulting role and travel grant from Daiichi Sankyo, outside this work. M.K. reports funding to the institute from BMS, Roche and AstraZeneca/MedImmune and an advisory role for BMS, Roche, MSD and Daiichi Sankyo, outside the submitted work.